Kymera, raising $173M+, becomes the 48th biotech IPO of the year as 2020 surpasses 2019

Yet another biotech will hit Nasdaq on Friday, and this one marks a milestone for 2020.

Cambridge, MA-based Kymera has priced its IPO, announcing a public price of $20 per share and $173.7 million raise. That’s upsized from an initial range of $16 to $18 per share, and would give the company a market value north of $900 million.